The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance.
about
Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Treatment with 20(S)-ginsenoside Rg3 reverses multidrug resistance in A549/DDP xenograft tumors.Synthesis and biological evaluation of novel 5-chloro--(4-sulfamoylbenzyl) salicylamide derivatives as tubulin polymerization inhibitors
P2860
The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The novel toluidine sulphonami ...... d circumvents MDR1 resistance.
@en
The novel toluidine sulphonami ...... d circumvents MDR1 resistance.
@nl
type
label
The novel toluidine sulphonami ...... d circumvents MDR1 resistance.
@en
The novel toluidine sulphonami ...... d circumvents MDR1 resistance.
@nl
prefLabel
The novel toluidine sulphonami ...... d circumvents MDR1 resistance.
@en
The novel toluidine sulphonami ...... d circumvents MDR1 resistance.
@nl
P2093
P2860
P50
P356
P1476
The novel toluidine sulphonami ...... d circumvents MDR1 resistance.
@en
P2093
F McLaughlin
L A Carleton
P2860
P2888
P304
P356
10.1038/BJC.2013.537
P407
P577
2013-09-19T00:00:00Z
P5875
P6179
1041315239